AstraZeneca to License Owkin AI Scientist for Development of Novel Biopharma Agents

AstraZeneca is licensing Owkin’s AI Scientist, K Pro, for three years, integrating the service into IT infrastructure and decision workflows. The two companies previously joined forces to develop an AI germline breast cancer susceptibility gene (gBRCA) pre-screen solution.

The goal of this agreement is for AstraZeneca to build biopharma agents helping decision-making teams to access timely, data-rich insights. Owkin, which specializes in biological artificial superintelligence, will lead the end-to-end development of these AI agents running on K Pro.

Owkin Brings AI Expertise

According to Owkin, K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. The insights gained by the AstraZeneca team will predominantly impact questions of competitive intelligence. This, in turn, reduces reliance on manual analysis under established standards of governance, security, and enterprise.

“At Owkin, we believe the future of the pharmaceutical industry is agentic,” said company co-founder and CEO Thomas Clozel. “Our experience, multimodal data, and agentic infrastructure allows us to build various complex agents.”

Clozel continued by saying this supports Owkin’s pharmaceutical partners, including competitive intelligence agents, supporting faster executive decisions.

Other AstraZeneca Happenings

Regarding AstraZeneca and Owkin’s previous work, their gBRCA solution ruled out approximately 40% of patients unlikely to carry gBRCA mutations. Sensitivity for these results registered high, at 93%. That collaboration now continues at Waiv, which recently spun out of Owkin’s diagnostic division.

In other recent AstraZeneca news, the company said in March 2026 it will establish an innovation center in Shanghai. This facility will be a commercial cell therapy manufacturing and supply base, enabling end-to-end cell therapy capabilities in China.